Abstract
England has been heavily affected by the SARS-CoV-2 pandemic, with severe ‘lock-down’ mitigation measures now gradually being lifted. The real-time pandemic monitoring presented here has contributed to the evidence informing this pandemic management. Estimates on the 10th May showed lock-down had reduced transmission by 75%, the reproduction number falling from 2.6 to 0.61. This regionally-varying impact was largest in London of 81% (95% CrI: 77%–84%). Reproduction numbers have since slowly increased, and on 19th June the probability that the epidemic is growing was greater than 5% in two regions, South West and London. An estimated 8% of the population had been infected, with a higher proportion in London (17%). The infection-to-fatality ratio is 1.1% (0.9%–1.4%) overall but 17% (14%–22%) among the over-75s. This ongoing work will be key to quantifying any widespread resurgence should accrued immunity and effective contact tracing be insufficient to preclude a second wave.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a study that only analyses routinely collected surveillance data and is not a clinical trial requiring registration.
Funding Statement
This work was supported by the Medical Research Council (Unit programme number MC UU00002/11) in partnership with Public Health England. Prior to the pandemic, the project was developed under a grant from the National Institute for Health Research (HTA Project: 11/46/03). None of the authors have received additional third-party payments or services for any aspects of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approvals are required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in the manuscript are routinely collected surveillance data on the ongoing CoVID-19 pandemic. We are in the process of agreeing and appropriate level of aggregation under which these data can be made available in a public repository.